Q32 Bio (QTTB) CSO granted 37,500 RSUs and updates holdings

Rhea-AI Filing Summary

Violette Shelia M. reported acquisition or exercise transactions in this Form 4 filing.

Q32 Bio Inc. Chief Scientific Officer Shelia M. Violette received a grant of 37,500 restricted stock units on February 24, 2026, at no cash cost per unit. The RSUs vest in four equal installments: 25% after 6 months from the grant date and 25% after 12, 24, and 36 months, with each RSU representing one share of common stock.

After this award, she directly holds 93,069 common shares. She is also a manager of Violette Holdings LLC, which holds 36,277 common shares; she disclaims beneficial ownership of those indirect shares except to the extent of her pecuniary interest.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Violette Shelia M.

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	37,500	$0.00	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 93,069 shares (Direct); Common Stock — 36,277 shares (Indirect, By Violette Holdings LLC)

Footnotes (1)

1. The restricted stock units ("RSUs") vest in four equal installments, 25% shall vest 6 months from February 24, 2026 (the "Grant Date"), 25% shall vest 12 months from the Grant Date, 25% shall vest 24 months from the Grant Date, and 25% shall vest 36 months from Grant Date. Each RSU represents a contingent right to receive one share of Issuer common stock. Shares held by Violette Holdings LLC ("Violette Holdings"). The Reporting Person is a manager of Violette Holdings and disclaims beneficial ownership of these shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that she is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Violette Shelia M.

(Last) (First) (Middle)

Q32 BIO INC.

830 WINTER STREET

(Street)

WALTHAM MASSACHUSETTS 02451

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Q32 Bio Inc. [ QTTB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
02/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/24/2026		A(1)		37,500	A	$0	93,069	D
Common Stock								36,277	I	By Violette Holdings LLC(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The restricted stock units ("RSUs") vest in four equal installments, 25% shall vest 6 months from February 24, 2026 (the "Grant Date"), 25% shall vest 12 months from the Grant Date, 25% shall vest 24 months from the Grant Date, and 25% shall vest 36 months from Grant Date. Each RSU represents a contingent right to receive one share of Issuer common stock.

2. Shares held by Violette Holdings LLC ("Violette Holdings"). The Reporting Person is a manager of Violette Holdings and disclaims beneficial ownership of these shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that she is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose.

	/s/ Eric Bell, Attorney-in-Fact	03/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Q32 Bio (QTTB) report for Shelia M. Violette?

Q32 Bio reported its Chief Scientific Officer, Shelia M. Violette, received 37,500 restricted stock units. The RSUs were granted at no cash cost and each unit represents one share of common stock, forming part of her equity-based compensation package.

How do the new RSUs granted to Q32 Bio CSO vest over time?

The 37,500 RSUs granted to the Q32 Bio Chief Scientific Officer vest in four equal 25% installments. Vesting occurs 6, 12, 24, and 36 months from the February 24, 2026 grant date, gradually delivering common shares as long as conditions are met.

What are Shelia M. Violette’s direct and indirect Q32 Bio share holdings?

After the grant, Shelia M. Violette directly holds 93,069 Q32 Bio common shares. In addition, 36,277 shares are held indirectly through Violette Holdings LLC, where she is a manager, and she disclaims beneficial ownership except for any pecuniary interest.

Does the RSU grant to Q32 Bio’s CSO involve open-market buying or selling?

The RSU grant does not involve open-market buying or selling. It is recorded with transaction code A, indicating a grant or award acquisition at a price of $0.0000 per share, reflecting compensation rather than a market trade in Q32 Bio stock.

What does the Form 4 say about Violette Holdings LLC’s Q32 Bio shares?

Form 4 shows 36,277 Q32 Bio shares held by Violette Holdings LLC. Shelia M. Violette is a manager of this LLC and expressly disclaims beneficial ownership of these shares, except to the extent of any pecuniary interest she may have in the entity.